You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Quetiapine modified release tablets are indicated for:,Bipolar disorder
Maintenance treatment of bipolar I disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes.
Treatment of depressive episodes associated with bipolar disorder (see Section 4.2 Dose and method of administration).
Treatment of acute mania associated with bipolar I disorder as monotherapy or in combination with lithium or sodium valproate
Efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,Schizophrenia
Treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,Major depressive disorder
Treatment of recurrent major depressive disorder (MDD) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,Generalised anxiety disorder
Treatment of generalised anxiety disorder (GAD).
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Quetiapine modified release tablets are indicated for:,Bipolar disorder
Maintenance treatment of bipolar I disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes.
Treatment of depressive episodes associated with bipolar disorder (see Section 4.2 Dose and method of administration).
Treatment of acute mania associated with bipolar I disorder as monotherapy or in combination with lithium or sodium valproate
Efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,Schizophrenia
Treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,Major depressive disorder
Treatment of recurrent major depressive disorder (MDD) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,Generalised anxiety disorder
Treatment of generalised anxiety disorder (GAD).
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Quetiapine modified release tablets are indicated for:,Bipolar disorder
Maintenance treatment of bipolar I disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes.
Treatment of depressive episodes associated with bipolar disorder (see Section 4.2 Dose and method of administration).
Treatment of acute mania associated with bipolar I disorder as monotherapy or in combination with lithium or sodium valproate
Efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,Schizophrenia
Treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,Major depressive disorder
Treatment of recurrent major depressive disorder (MDD) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,Generalised anxiety disorder
Treatment of generalised anxiety disorder (GAD).
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Quetiapine modified release tablets are indicated for:,Bipolar disorder
Maintenance treatment of bipolar I disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes.
Treatment of depressive episodes associated with bipolar disorder (see Section 4.2 Dose and method of administration).
Treatment of acute mania associated with bipolar I disorder as monotherapy or in combination with lithium or sodium valproate
Efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,Schizophrenia
Treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,Major depressive disorder
Treatment of recurrent major depressive disorder (MDD) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,Generalised anxiety disorder
Treatment of generalised anxiety disorder (GAD).
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Quetiapine modified release tablets are indicated for:,Bipolar disorder
Maintenance treatment of bipolar I disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes.
Treatment of depressive episodes associated with bipolar disorder (see Section 4.2 Dose and method of administration).
Treatment of acute mania associated with bipolar I disorder as monotherapy or in combination with lithium or sodium valproate
Efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,Schizophrenia
Treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,Major depressive disorder
Treatment of recurrent major depressive disorder (MDD) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,Generalised anxiety disorder
Treatment of generalised anxiety disorder (GAD).
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
